AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2005, p. 1943-1948, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.1943-1948.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary

George G. Zhanel,1,2,3* Christel Johanson,1 Nancy Laing,1 Tamiko Hisanaga,1 Aleksandra Wierzbowski,1 and Daryl J. Hoban1,2

Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, and Departments of Clinical,1 Microbiology,2 Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada3

Received 20 October 2004/ Returned for modification 6 December 2004/ Accepted 19 January 2005


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The present study, using an in vitro model, assessed telithromycin pharmacodynamic activity at simulated clinically achievable free-drug concentrations in serum (S) and epithelial lining fluid (ELF) against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae. Two macrolide-susceptible (PCR negative for both mefE and ermB) and 11 efflux-producing macrolide-resistant [PCR-positive for mefE and negative for ermB) S. pneumoniae strains with various telithromycin MICs (0.015 to 1 µg/ml) were tested. The steady-state pharmacokinetics of telithromycin were modeled, simulating a dosage of 800 mg orally once daily administered at time 0 and at 24 h (free-drug maximum concentration [Cmax] in serum, 0.7 µg/ml; half-life [t1/2], 10 h; free-drug Cmax in ELF, 6.0 µg/ml; t1/2, 10 h). Starting inocula were 106 CFU/ml in Mueller-Hinton Broth with 2% lysed horse blood. Sampling at 0, 2, 4, 6, 12, 24, and 48 h assessed the extent of bacterial killing (decrease in log10 CFU/ml versus initial inoculum). Free-telithromycin concentrations in serum achieved in the model were Cmax 0.9 ± 0.08 µg/ml, area under the curve to MIC (AUC0-24 h) 6.4 ± 1.5 µg · h/ml, and t1/2 of 10.6 ± 0.6 h. Telithromycin-free ELF concentrations achieved in the model were Cmax 6.6 ± 0.8 µg/ml, AUC0-24 h 45.5 ± 5.5 µg · h/ml, and t1/2 of 10.5 ± 1.7 h. Free-telithromycin S and ELF concentrations rapidly eradicated efflux-producing macrolide-resistant S. pneumoniae with telithromycin MICs up to and including 0.25 µg/ml and 1 µg/ml, respectively. Free-telithromycin S and ELF concentrations simulating Cmax/MIC ≥ 3.5 and AUC0-24 h/MIC ≥ 25 completely eradicated (≥4 log10 killing) macrolide-resistant S. pneumoniae at 24 and 48 h. Free-telithromycin concentrations in serum simulating Cmax/MIC ≥ 1.8 and AUC0-24 h/MIC ≥ 12.5 were bacteriostatic (0.1 to 0.2 log10 killing) against macrolide-resistant S. pneumoniae at 24 and 48 h. In conclusion, free-telithromycin concentrations in serum and ELF simulating Cmax/MIC ≥ 3.5 and AUC0-24 h/MIC ≥ 25 completely eradicated (≥4 log10 killing) macrolide-resistant S. pneumoniae at 24 and 48 h.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Macrolide (azithromycin, clarithromycin, and erythromycin) resistance in Streptococcus pneumoniae is presently ~25% in the United States and approximately 13% in Canada (1, 3, 28, 31). Macrolide resistance in S. pneumoniae involves alteration of the ribosomal target site or production and utilization of an efflux mechanism (6, 9, 29, 33). The production of ribosomal methylase, which alters the ribosomal target site of the macrolide, is usually coded for by the ermB gene and confers broad macrolide, lincosamide, and streptogramin B resistance (6, 9, 29, 33). The second mechanism, which results in macrolide efflux, is coded by the mefA or mefE genes (6, 9, 29, 33). Efflux is macrolide specific (14- and 15-membered macrolides only) and does not affect the lincosamide or streptogramins (28, 32). Note that ermB-positive S. pneumoniae strains generally exhibit high-level (MIC90 ≥ 64 µg/ml) macrolide resistance, while mefA- or mefE-positive S. pneumoniae strains exhibit low- to moderate-level resistance (MIC90 4 µg/ml) (6, 9, 29, 33). Both of these mechanisms are transmissible to other isolates (6, 9, 29, 33). Presently, in North America, mefE-positive S. pneumoniae is more common than ermB-positive S. pneumoniae and mefE strains make up the majority of macrolide-resistant S. pneumoniae strains (6, 9). In many European countries, ermB-positive S. pneumoniae strains are more prevalent (28, 32).

Although reports associating macrolide-resistant S. pneumoniae with macrolide clinical failure in the treatment of community-acquired respiratory infections are available, they are not that common (24).

Ketolides are a new class of semisynthetic agents derived from erythromycin A and are designed specifically to combat respiratory tract pathogens that have acquired resistance to macrolides (5, 7, 8, 11, 22, 26, 32). The main structural difference between ketolides and the macrolides is the lack of L-cladinose sugar at position 3 of the erythronolide A ring and its replacement with a 3-keto group (28, 33). Telithromycin and cethromycin (formerly ABT-773) have excellent in vitro activity against many pathogens causing community-acquired respiratory infections, including penicillin and macrolide-resistant strains (5-9, 22, 26, 28, 32). Ketolides demonstrate potent activity against most macrolide-resistant streptococci, including ermB- and mefA- or mefE-positive Streptococcus pneumoniae (5-9, 22, 26, 28, 32). Their pharmacokinetics display a long half-life (t1/2) as well as extensive tissue distribution and uptake into respiratory tissues and fluids, allowing for once-daily (OD) dosing (4, 12, 14, 15, 16, 19, 27). Presently only limited data are available on the pharmacodynamic activity of ketolides against macrolide-resistant S. pneumoniae in comparison to macrolides (13, 34).

The purpose of this study was to assess the pharmacodynamic activity of the ketolide telithromycin at simulated clinically achievable free-drug concentrations in serum (S) and epithelial lining fluid (ELF) against efflux-producing mefE macrolide-resistant S. pneumoniae.


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Bacterial strains and culture conditions. Two macrolide-susceptible and 11 efflux-producing mefE macrolide-resistant strains of S. pneumoniae were evaluated (Table 1). As the mef gene in S. pneumoniae occurs as two variants, discrimination between mefA and mefE was performed by PCR-restriction fragment length polymorphism analysis according to a previously described protocol (2). Isolates were obtained from the Canadian Respiratory Organism Susceptibility Study (CROSS) (31). Telithromycin and azithromycin MICs are depicted in Table 1. The wild-type strains 11771 and 11888 were PCR-negative for mefA, mefE, and ermB and were macrolide-susceptible (azithromycin MIC ≤ 0.5 µg/ml). Macrolide-resistant (azithromycin MIC ≥ 2 µg/ml) strains were PCR-positive for mefE and PCR-negative for ermB (Table 1). Isolates were chosen to represent a variety of telithromycin MICs (0.015 to 1 µg/ml). The method and conditions used for PCR detection of mefE and ermB genotypes have been previously described (9).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Telithromycin susceptibilities of macrolide-susceptible and macrolide-resistant mefE S. pneumoniae

 
Antibiotic preparation and susceptibility testing. Antibiotics were obtained as laboratory grade powders from their respective manufacturers. Stock solutions were prepared, and dilutions were made according to previously described methods (17). Following two subcultures from frozen stock, antibiotic MICs were determined by the NCCLS broth microdilution method (17, 18). All MIC determinations were performed in triplicate on separate days.

In vitro pharmacodynamic model. The in vitro pharmacodynamic model used in this study has been previously described (21). Logarithmic phase cultures were prepared using a 0.5 McFarland (108 CFU/ml) standard by suspending several colonies in cation-supplemented Mueller-Hinton broth with 2% lysed horse blood (Oxoid, Nepean, Ontario, Canada) (pH 7.1). This suspension was diluted 1:100, and 20 µl of the diluted suspension was further diluted in 60 ml of cation-supplemented Mueller-Hinton broth with 2% lysed horse blood. The resulting suspension was allowed to grow overnight at 35°C in ambient air (21, 30, 34). After a maximum of 17 h, the suspension was further diluted to 1:10 and 60 ml of the diluted suspension was added to the in vitro pharmacodynamic model. Viable bacterial counts consistently yielded a starting inoculum of approximately 106 CFU/ml (21, 30, 34). This final inoculum was introduced into the central compartment (volume, 610 ml) of the in vitro pharmacodynamic model.

Pharmacokinetics and pharmacodynamics simulated. Telithromycin was modeled based upon data obtained from previous publications (our target or simulated concentrations), simulating steady-state pharmacokinetics after a dosage of 800 mg orally (p.o.) OD (4, 12, 16, 28, 32). Thus, if after the administration of telithromycin at 800 mg, the maximum serum concentration (Cmax) was ~2.2 µg/ml (and the serum protein binding was ~70%) (4, 28, 32), it was assumed that the free Cmax in serum was ~0.7 µg/ml. Thus, in serum (S) we simulated the maximum concentration [Cmax] at 0.7 µg/ml, t1/2 10 h. For epithelial lining fluid (ELF), it has been reported that the Cmax of telithromycin after 800 mg is ~15 µg/ml (12). As the protein binding of telithromycin in ELF was not known, it was assumed to be similar to that of serum (70%) and thus only the likely concentration of free drug in ELF (Cmax ~ 6.0 µg/ml) was simulated. Not knowing what the exact t1/2 of telithromycin was in ELF, we chose to simulate a t1/2 for telithromycin of ~10 h for both serum and ELF and to simulate a slightly higher free-drug concentration in ELF (Cmax ~ 6.0 µg/ml) knowing this would result in a larger AUC0-24 h. Telithromycin was administered once at time 0 and as a second dose at 24 h. Thus, two doses were administered every 24 h for 48 h. Pharmacodynamic experiments were performed in ambient air at 37°C. Samples were collected at 0, 1, 2, 4, 6, 12, 24, and 48 h for both pharmacokinetic and pharmacodynamic assessment (21, 30, 34). Telithromycin concentrations in the pharmacodynamic model were determined microbiologically with a bioassay (21, 30, 34). Actual or achieved telithromycin concentrations were determined in quadruplicate using Bacillus subtilis ATCC 6633 as the test organism with lower limits of quantification of 0.03 µg/ml. The plates were incubated aerobically for 18 h at 37°C. Concentrations were determined in relation to the diameters of the inhibition zones caused by the known concentrations from the standard series. The correlation coefficient of this assay was 0.80. Intra- and interrun variability of quality control samples were ≤6.5% and ≤5.8%, respectively. The actual or achieved concentrations of telithromycin and not the target or simulated concentrations were used in pharmacodynamic interpretations (e.g., Cmax/MIC and AUC0-24 h/MIC). Pharmacodynamic parameters of Cmax/MIC, AUC0-24 h/MIC, and time above the MIC (T > MIC) were derived from the actual or achieved telithromycin concentrations obtained in the model relative to the MIC of the strain in question.

Pharmacodynamic sampling was performed over 48 h with viable bacterial counts assessed by plating serial 10-fold dilutions onto cation-supplemented Mueller-Hinton agar with 2.0% lysed horse blood. Plates were incubated for 24 h at 37°C in ambient air. The lowest dilution plated was 0.1 ml of undiluted sample, and the lowest level of detection was 200 CFU/ml (2.0 log10) (21, 30, 34).


   RESULTS
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Table 1 shows the MICs of telithromycin and azithromycin against the clinical isolates utilized in this study. Strains were chosen to include macrolide-susceptible (wild-type) as well as low-level (MIC 2 to 4 µg/ml), intermediate (MIC 8 µg/ml), and high-level (MIC 16 µg/ml) macrolide-resistant mefE strains and ermB-positive S. pneumoniae. As well, isolates were chosen to represent a wide distribution of telithromycin MICs ranging from 0.008 µg/ml to 1 µg/ml. As shown in Table 1, all mefE strains were susceptible to clindamycin.

Pharmacokinetics. Target (simulated) and actual (achieved) pharmacokinetic parameters of telithromycin after simulating a dosage of 800 mg p.o. OD (free serum and free epithelial lining fluid) achieved in the model were similar (Table 2). Target (simulated) and actual (achieved) pharmacokinetic parameters of telithromycin achieved in serum were as follows: free drug Cmax, 0.7 µg/ml (occurring at t = 0); AUC0-24 h, 4.5 µg · h/ml; t1/2, 10 h; and Cmax, 0.9 ± 0.08 (± standard deviation [SD]) µg/ml (occurring at t = 0); AUC0-24 h, 6.4 ± 1.5 (± SD) µg · h/ml; t1/2, 10.6 ± 0.6 (± SD) h, respectively. Telithromycin target (simulated) and actual (achieved) pharmacokinetic parameters achieved under free-drug conditions in ELF were CELF-free maximum, 6.0 µg/ml (occurring at t = 0); AUC0-24 h, 38.6 µg · h/ml; t1/2, 10 h; and CELF-free maximum, 6.6 ± 0.8 (± SD) µg/ml (occurring at t = 0); AUC0-24 h, 45.5 ± 5.5 (± SD) µg·h/ml; t1/2, 10.5 ± 1.7 (± SD) h, respectively.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Simulated (target) and achieved (actual) telithromycin pharmacokinetics

 
Pharmacodynamics. Table 3 describes the killing of S. pneumoniae with achieved telithromycin free-drug concentrations in serum. Free-telithromycin concentrations in serum resulted in bactericidal (≥3.0 log10 CFU/ml decrease versus initial inoculum) activity as early as 4 h for strains with telithromycin MICs ≤ 0.12 µg/ml (Table 3). This bactericidal activity was maintained for the entire 48 h of the experimental period. For strain 17258 with a telithromycin MIC of 0.25 µg/ml, free-telithromycin concentrations in serum were bacteriostatic (≤3.0 log10 CFU/ml decrease versus initial inoculum) for the first 12 h followed by complete bacterial eradication (≥4.0 log10 CFU/ml decrease versus initial inoculum) at 24 and 48 h (Table 3). Free-telithromycin concentrations in serum resulted in bacteriostatic (≤3.0 log10 CFU/ml decrease versus initial inoculum) activity over the entire 48 h period for strains with telithromycin MIC 0.5 µg/ml (Table 3). For strains with telithromycin MIC of 1 µg/ml, free-telithromycin concentrations in serum were bacteriostatic (≤3.0 log10 CFU/ml decrease versus initial inoculum) over the first 6 to 12 h followed by rapid regrowth at 24 and 48 h (Table 3).


View this table:
[in this window]
[in a new window]
  		TABLE 3. Telithromycin killing of S. pneumoniae at simulated free-drug concentrations in serum and epithelial lining fluid

 
Table 3 also describes the killing of S. pneumoniae with achieved free-telithromycin concentrations in epithelial lining fluid (ELF). Free-telithromycin concentrations in ELF resulted in bactericidal (≥3.0 log10 CFU/ml decrease versus initial inoculum) activity as early as 2 h for strains with telithromycin MICs ≤ 0.12 µg/ml (Table 3). This bactericidal activity was maintained for the entire 48 h of the experimental period. For strains with telithromycin MICs of 0.25 µg/ml and 0.5 µg/ml, free-telithromycin concentrations in ELF were bacteriostatic (≤3.0 log10 CFU/ml decrease versus initial inoculum) for the first 6 h followed by complete bacterial eradication (≥4.0 log10 CFU/ml decrease versus initial inoculum) at 12, 24, and 48 h (Table 3). For strains with telithromycin MICs of 1 µg/ml, free-telithromycin concentrations in ELF were bacteriostatic (≤3.0 log10 CFU/ml decrease versus initial inoculum) for the first 4 to 6 h followed by complete bacterial eradication (≥4.0 log10 CFU/ml decrease versus initial inoculum) at 12 to 24 h (Table 3).

The pharmacodynamic parameters associated with bacterial inhibition (decrease in log10 CFU/ml at 24 h versus initial inoculum) by telithromycin at simulated achieved free-drug concentrations in serum as well as in ELF are depicted in Tables 4, 5, and 6. Free-telithromycin concentrations in serum and ELF simulating Cmax/MIC ≥ 3.5 and AUC0-24 h/MIC ≥ 25 (time above the MIC [T > MIC] of 84%, shown for comparative purposes only) completely eradicated (≥4 log10 killing) macrolide-resistant S. pneumoniae at 24 and 48 h. Free-telithromycin concentrations in serum simulating Cmax/MIC ≥ 1.8 and AUC0-24 h/MIC ≥ 12.5 (time above the MIC [T > MIC] of 42%, shown for comparative purposes only) were bacteriostatic (0.1 to 0.2 log10 killing) against macrolide-resistant S. pneumoniae at 24 and 48 h. Free-telithromycin concentrations in serum simulating Cmax/MIC ≤ 0.9 and AUC0-24 h/MIC ≤ 6.3 (time above the MIC [T > MIC] of 0%, shown for comparative purposes only) resulted in regrowth of macrolide-resistant S. pneumoniae at 24 and 48 h.


View this table:
[in this window]
[in a new window]
  		TABLE 4. Pharmacodynamics of telithromycin versus macrolide-susceptible and macrolide-resistant S. pneumoniae (T > MIC)a

 

View this table:
[in this window]
[in a new window]
  		TABLE 5. Pharmacodynamics of telithromycin versus macrolide-susceptible and macrolide-resistant S. pneumoniae (Cmax/MIC)a

 

View this table:
[in this window]
[in a new window]
  		TABLE 6. Pharmacodynamics of telithromycin vs. macrolide-susceptible and macrolide-resistant S. pneumoniae (AUC0-24 h/MIC)

 

   DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In a previous study, using this same in vitro model, we assessed telithromycin pharmacodynamic activity (against macrolide-susceptible and macrolide-resistant S. pneumoniae) at simulated clinically achievable free-drug concentrations in serum (S) and epithelial lining fluid (ELF) against strains with telithromycin MICs of 0.008 to 0.03 µg/ml. Against these very susceptible isolates, telithromycin serum and epithelial lining fluid concentrations resulted in eradication from the model in 4 h with no regrowth over 48 h (34). The purpose of this study was to assess the pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid (ELF) against efflux-producing macrolide-resistant S. pneumoniae with various telithromycin MICs (from 0.008 to 1 µg/ml). In this study, we modeled telithromycin based upon data obtained from previous publications of simulations of steady-state pharmacokinetics after a dosage of 800 mg p.o. OD (4, 12, 16, 28, 32). Thus, if after the administration of telithromycin 800 mg, the maximum concentration (Cmax) in serum was ~2.2 µg/ml (and the serum protein binding was ~70%) (4, 28, 32), it was assumed that the free Cmax in serum was ~0.7 µg/ml. As our pharmacodynamic model contains no high molecular weight protein such as albumin, no protein binding occurs in the model and thus all drug that is added is non-protein-bound or free drug capable of crossing bacterial membranes and exerting a microbiological or pharmacological response. Assuming that, after administration of 800 mg of telithromycin, only the free drug in serum (Cmax, 0.7 µg/ml) is active and not the entire protein-bound and free drug (Cmax, 2.2 µg/ml) may underestimate the pharmacodynamic activity of telithromycin in serum. However, we chose in this study to study only the pharmacodynamic potential of the free drug. Thus, in serum (S) we simulated the maximum concentration at a Cmax of 0.7 µg/ml and a t1/2 of 10 h. For epithelial lining fluid (ELF), it has been reported that the Cmax of telithromycin after 800 mg is ~15 µg/ml (12). As the protein binding of telithromycin in ELF was not known, it was assumed to be similar to that of serum (70%) and thus only the likely concentration of free drug in ELF (Cmax ~ 6.0 µg/ml) was simulated. We chose to simulate a Cmax in ELF of ~6.0 µg/ml and not 4.5 µg/ml because it has been reported that the t1/2 of telithromycin in ELF is longer than in serum (16). Not knowing what the exact t1/2 of telithromycin was in ELF, we chose to simulate a t1/2 for telithromycin of ~10 h for both serum and ELF and to simulate a slightly higher free-drug concentration in ELF (Cmax ~ 6.0 µg/ml) knowing this would result in a larger AUC0-24 h. As with serum, it was assumed that only the free drug in the ELF (Cmax ~ 6.0 µg/ml) is active and not the entire protein-bound and free drug (Cmax ~ 15 µg/ml). It is true that these assumptions may underestimate the pharmacodynamic activity of telithromycin in ELF; however, we chose in this study only to examine the pharmacodynamic potential of the free drug. It should be mentioned that the exact methods of how best to model ELF concentrations using an in vitro model are under debate.

Using the above-described pharmacodynamic model, we clearly showed that free-telithromycin concentrations in ELF rapidly eradicated macrolide-resistant S. pneumoniae with telithromycin MICs ranging from 0.015 µg/ml to 1 µg/ml (Table 3). Free-telithromycin concentrations in serum rapidly eradicated macrolide-resistant S. pneumoniae with telithromycin MICs up to and including 0.25 µg/ml (Table 3). Pharmacodynamically, free telithromycin concentrations in serum and ELF simulating Cmax/MIC ≥ 3.5 and AUC0-24 h/MIC ≥ 25 (time above the MIC [T > MIC] of 84%) completely eradicated (≥4 log10 killing) macrolide-resistant S. pneumoniae at 24 and 48 h (Tables 4, 5, and 6). It should be clear that although the pharmacodynamics of telithromycin correlate with Cmax/MIC and AUC0-24 h/MIC, we also showed the T > MIC for comparative purposes only and not to imply that the pharmacodynamics of telithromycin correlate with T > MIC.

Comparing the ketolide telithromycin to the macrolide azithromycin, we previously reported that azithromycin serum and epithelial lining fluid concentrations rapidly eradicated macrolide-susceptible S. pneumoniae but did not eradicate macrolide-resistant S. pneumoniae regardless of resistance phenotype (30). It should, however, be mentioned that our model simulates an immunocompromised host as no component of the immune system is added to the model. Thus, whether in an immunocompetent host, azithromycin can eradicate macrolide-resistant S. pneumoniae is not known. As the majority of S. pneumoniae in North America are macrolide-susceptible (~75% in the United States and ~87% in Canada), this may help to explain the excellent bacteriological and clinical outcomes obtained with macrolides (such as azithromycin) versus comparator antibiotics in clinical studies of community-acquired respiratory infections, such as community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute sinusitis, and otitis media, where S. pneumoniae is a key pathogen (28). However, the rapid and extensive eradication of macrolide-resistant S. pneumoniae by telithromycin, when simulating clinically achievable free-drug concentrations in serum and epithelial ling fluid in this study, suggests that ketolides offer an advantage compared to macrolides such as azithromycin which are not able to eradicate macrolide-resistant S. pneumoniae (whether mefE or ermB) in serum, epithelial lining fluid, or middle ear fluid (30). These differences may help explain why ketolides compared to macrolides may result in reductions in hospitalization rates when treating community-acquired pneumonia (20, 25).

Only limited data are available regarding the pharmacodynamic properties of ketolides (4, 10, 13, 23, 34). Jacobs et al. demonstrated that against gram-positive cocci such as S. pneumoniae, telithromycin demonstrated postantibiotic effects of 0.3 to 3.8 h and postantibiotic sub-MIC effects of 0.8 to 4.6 h (10). It has been reported that telithromycin is a concentration-dependent bacterial killer with eradication being related to AUC/MIC and Cmax/MIC (4, 13, 14, 19, 34). Odenholt et al. reported that against S. pneumoniae, telithromycin demonstrated extremely fast (~1 h) bactericidal (≥3 log10 killing) activity with Cmax/MIC ≥ 37.5 (23). Kim et al. using a murine pneumococcal pneumonia model reported that free Cmax/MIC and AUC0-24 h/MIC best explained the relationship between ketolide (cethromycin) drug exposure and reductions in viable bacterial counts (13). These authors documented free-drug Cmax/MIC of 1 and AUC0-24 h/MIC of 50 as resulting in bacteriostatic effects and maximal survival at free-drug Cmax/MIC and AUC0-24 h/MICs twice these amounts (13). In this study, we also observed very rapid bactericidal activity (within 4 h) against S. pneumoniae in simulations of free-telithromycin concentrations in serum and ELF, with pharmacodynamics of Cmax/MIC ≥ 7 and area under the curve to MIC (AUC0-24 h/ MIC) ≥ 50 (Tables 5 and 6).

In conclusion, telithromycin concentrations in serum and epithelial lining fluid rapidly eradicated efflux-producing macrolide-resistant S. pneumoniae with telithromycin MICs up to and including 0.25 and 1 µg/ml, respectively. Free-telithromycin concentrations in serum and ELF simulating Cmax/MIC ≥ 3.5 and area under the curve to MIC (AUC0-24 h/MIC) ≥ 25 completely eradicated (≥4 log10 killing) macrolide-resistant S. pneumoniae at 24 and 48 h. Finally, it should once again be mentioned that the exact methods of how best to model in vivo ELF concentrations using an in vitro model are under debate.


   ACKNOWLEDGMENTS
 
The expert secretarial assistance of M. Tarka is appreciated.

This study was supported in part by the University of Manitoba.


   FOOTNOTES
 
* Corresponding author. Mailing address: Microbiology, Health Sciences Centre, MS673-820 Sherbrook St., Winnipeg, Manitoba R3A 1R9, Canada. Phone: 204 787 4902. Fax: 204 787 4699. E-mail: ggzhanel{at}pcs.mb.ca. Back


   REFERENCES
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Butler, J. C., J. Hofmann, M. S. Cetron, J. A. Elliot, R. R. Facklam, and R. F. Breiman. 1996. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J. Infect. Dis. 174:986-993.[Medline]
  2. Del Grosso, M., F. Iannelli, C. Messina, M. Santagati, N. Petrosillo, S. Stefani, G. Pozzi, and A. Pantosti. 2002. Macrolide efflux genes mefA and mefE are carried by different genetic elements in Streptococcus pneumoniae. J. Clin. Microbiol. 40:774-778.[Abstract/Free Full Text]
  3. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffam, and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.[Abstract/Free Full Text]
  4. Drusano, G. 2001. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: Focus on telithromycin. Clin. Microbiol. Infect. 7(Suppl. 3):24-29.
  5. Farrell, D., and D. Felmingham. 2004. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999-2003. Antimicrob. Agents Chemother. 48:1882-1884.[Abstract/Free Full Text]
  6. Farrell, D. J., and S. G. Jenkins. 2004. Distribution across the USA of macrolide resistance and macrolide resistance mechanism among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J. Antimicrob. Chemother. 54(Suppl. 1):17-22.[Abstract/Free Full Text]
  7. Farrell, D. J., I. Morrissey, S. Bakker, S. Buckridge, and D. Felmingham. 2004. In vitro activities of telithromycin linezolid quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob. Agents Chemother. 48:3169-3171.[Abstract/Free Full Text]
  8. Hoban, D. J., G. G. Zhanel, and J. A. Karlowsky. 1999. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Diagn. Microbiol. Infect. Dis. 35:37-44.[CrossRef][Medline]
  9. Hoban, D. J., A. Wierzbowski, K. A. Nichol, and G. G. Zhanel. 2001. Macrolide-resistant Streptococcus pneumoniae in Canada from 1998-1999: prevalence of mefA and ermB and susceptibility to ketolides. Antimicrob. Agents Chemother. 45:2147-2150.[Abstract/Free Full Text]
  10. Jacobs, M. R., S. Bajaksouzian, and P. C. Appelbaum. 2003. Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 gram-positive cocci. J. Antimicrob. Chemother. 52(5):809-812.[Abstract/Free Full Text]
  11. Jorgensen, J. H., S. A. Crawford, M. L. McElmeel, and C. G. Whitney. 2004. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48:605-607.[Abstract/Free Full Text]
  12. Khair, O. A., J. M. Andrews, D. Honeybourne, G. Jevons, F. Vacheron, and R. Wise. 2001. Lung concentrations of telithromycin after oral dosing. J. Antimicrob. Chemother. 47:837-840.[Abstract/Free Full Text]
  13. Kim, M., W. Zhou, P. R. Tessier, D. Xuan, M. Ye, C. H. Nightingale, and D. P. Nicolau. 2002. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob. Agents Chemother. 46:3185-3192.[Abstract/Free Full Text]
  14. Maglio, D., D. P. Nicolau, and C. H. Nightingale. 2003. Impact of pharmacodynamics on dosing of macrolides, azalides, ketolides. Infect. Dis. Clin. North Am. 17:563-577.[Medline]
  15. Muller-Serieys, C., P. Soler, C. Cantalloube, F. Lemaitre, H. P. Gia, F. Brunner, and A. Andremont. 2001. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob. Agents Chemother. 45:3104-3108.[Abstract/Free Full Text]
  16. Muller-Serieys, C., J. Andrews, F. Vacheron, and C. Cantalloube. 2004. Tissue kinetics of telithromycin, the first ketolide antibacterial. J. Antimicrob. Chemother. 53:149-157.[Abstract/Free Full Text]
  17. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, 5th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  18. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing: supplemental tables. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  19. Nicolau, D. P. 2004. Clinical use of antimicrobial pharmacodynamic profiles to optimize treatment outcomes in community-acquired bacterial respiratory tract infections: Applications to telithromycin. Exp. Opin. Pharmacother. 5:229-235.[Medline]
  20. Niederman, M. S., J. R. Chang, J. Stewart, R. Nusrat, and R. B. Nieman. 2004. Comparison of hospitalization rates in patients with community acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Curr. Med. Res. Opin. 20:740-756.
  21. Noreddin, A., D. Roberts, K. Nichol, A. Wierzbowski, D. J. Hoban, and G. G. Zhanel. 2002. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob. Agents Chemother. 46:4029-4034.[Abstract/Free Full Text]
  22. Novotny, G. W., L. Jakobsen, N. M. Andrewsen, J. Poehlsgaard, and S. Douthwaite. 2004. Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA. Antimicrob. Agents Chemother. 48:3677-3683.[Abstract/Free Full Text]
  23. Odenholt, I., E. Lowdin, and O. Cars. 2001. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob. Agents Chemother. 45:23-29.[Abstract/Free Full Text]
  24. Rzeszutek, M., A. Wierzbowski, J. Conly, W. Bishai, D. Hoban, and G. G. Zhanel. 2004. A review of clinical failures involving macrolide-resistant Streptococcus pneumoniae. Int. J. Antimicrob. Agents 24:95-104.[CrossRef][Medline]
  25. Tellier, G., J. R. Chang, C. V. Asche, B. Lavin, J. Stewart, and S. D. Sullivan. 2004. Comparison of hospitalization rates in patients with community acquired pneumonia treated with telithromycin for 5 or 7 days or with clarithromycin for 10 days. Curr. Med. Res. Opin. 20:739-747.[CrossRef][Medline]
  26. Walsh, F., F. Carnegy, J. Willcock, and S. Amyes. 2004. Comparative in vitro activity of telithromycin against macrolide resistant and susceptible Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. J. Antimicrob. Chemother. 53:793-796.[Abstract/Free Full Text]
  27. Zhanel, G. G. 2001. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Curr. Infect. Dis. Rep. 3:29-34.[Medline]
  28. Zhanel, G. G., M. Dueck, D. J. Hoban, L. Vercaigne, J. Embil, S. S. Gin, and J. A. Karlowsky. 2001. Macrolides and ketolides: a review focusing on respiratory infections. Drugs 61:443-498.[CrossRef][Medline]
  29. Zhanel, G. G., and J. A. Karlowsky. 2001. Ribosomal resistance: emerging problems and potential solutions. Curr. Infect. Dis. Rep. 1:459-463.
  30. Zhanel, G. G., M. DeCorby, A. Noreddin, C. Mendoza, A. Cumming, K. Nichol, A. Wierzbowski, and D. J. Hoban. 2003. Pharmacodynamic activity of azithromycin against macrolide-susceptible and macrolide-resistant (PCR positive mefA or ermB) Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid (ELF) and middle ear fluid (MEF) concentrations. J. Antimicrob. Chemother. 52:83-88.[Abstract/Free Full Text]
  31. Zhanel, G. G., L. Palatnick, K. Nichol, T. Bellyou, D. Low, and D. J. Hoban. 2003. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47:1867-1874.[Abstract/Free Full Text]
  32. Zhanel, G. G., A. Wierzbowski, T. Hisanaga, and D. J. Hoban. 2004. The use of ketolides in the treatment of upper respiratory tract infections. Clin. Infect. Dis. Rep. 6:191-199.
  33. Zhanel, G. G., T. Hisanaga, K. Nichol, A. Wierzbowski, and D. J. Hoban. 2003. Emerging treatments for macrolide resistant bacteria. Exp. Opin. Emerg. Drugs 8:297-321.
  34. Zhanel, G.G., C. Johanson, T. Hisanaga, C. Mendoza, N. Laing, A. Noreddin, A. Wierzbowski, and D. J. Hoban. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J. Antimicrob. Chemother. 54:1072-1077.

Antimicrobial Agents and Chemotherapy, May 2005, p. 1943-1948, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.1943-1948.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS